Table 1 Clinical and demographic characteristics of patients with BSIs receiving appropriate and inappropriate therapy

Age, years, median (IQR)

67 (54–79)

66(54–79)

70.5(54.75.5–80)

Male sex

104(50.73%)

69(46.94%)

35(60.34%)

Comorbidities

 Cardiovascular disease

60(29.27%)

41(27.89%)

19(32.76%)

 Diabetes

70(34.15%)

52(35.37%)

18(31.03%)

 Chronic kidney disease

27(13.17%)

21(14.29%)

6(10.34%)

 Chronic liver disease

6(2.93%)

4(2.72%)

2(3.45%)

 COPD

6(2.93%)

3(2.04%)

3(5.17%)

 Solid cancer

28(13.66%)

22(14.97%)

6(10.34%)

 Immunosuppression

14(6.83%)

11(7.48%)

3(5.17%)

Site of infection

 Pulmonary

49(23.90%)

33(22.45%)

16(27.59%)

 Intra-abdominal

48(23.41%)

36(24.49%)

12(20.69%)

 Vascular catheter

14(6.83%)

7(4.76%)

7(12.07%)

 Urinary tract

50(24.39%)

41(27.89%)

9(15.52%)

 Skin or soft tissue

19(9.27%)

16(10.88%)

3(5.17%)

 Bone or Joint

9(4.39%)

6(4.08%)

3(5.17%)

 Primary BSI

16(7.80%)

8(5.44%)

8(13.79%)

Charlson comorbidity index score

1(0–2)

0(1–2)

0(1–2)

Pitt bacteraemia score

1(0−3.5)

1(0–3)

1(0–4)

SOFA Score on Culture Day

3(0−6.5)

2(0–6)

3(0–7)

APACHE II score

17(12−21.75)

17(12.25–21.75)

17(9.5–21.5)

ICU admission

112(54.63%)

77(52.38%)

35(60.34%)

Length of ICU stay after BSI, days

12(6.25–26.75)

9.5(5–21)

19.5(10.25–32.75)

Hospital length of stay after BSI, days

22(14–37)

19(13–32)

30(15.75–41.25)

Type of acquisition

 Healthcare-associated

36(17.56%)

19(12.93%)

17(29.31%)

 Nosocomial

169(82.44%)

128(87.07%)

41(70.69%)

Mechanical ventilation

50(24.39%)

25(17.01%)

25(43.10%)

AKI

25(12.20%)

12(8.16%)

13(22.41%)

Septic shock

69(33.66%)

48(32.65%)

21(36.21%)